Voyager Therapeutics CEO and leadership

Phil focuses on creating and building companies that develop breakthrough therapies for orphan genetic diseases. He is passionate about working with patient groups, and helping to unite those suffering from rare diseases in order to foster a support network and potentially improve patient outcomes.

Phil has authored or co-authored more than 100 articles in scholarly journals and has published seven books including most recently Orphan: The Quest to Save Children with Rare Genetic Disorders. Phil currently serves on the Advisory Board to the Boston University School of Public Health, and has served as a trustee emeritus of Cornell University, an Overseer of Weill Cornell Medical College.

Allen Nunnally is a Chief Business Officer at VOYAGER THERAPEUTICS, INC.. He has worked as VP:Corporate & Business Development at VOYAGER THERAPEUTICS, INC.. Allen attended Boston University and Amherst College.

Michelle Quinn Smith brings over 30 years of experience in human resources to Voyager. Ms. Smith served most recently as Senior Director of Human Resources at Flagship Pioneering as part of Flagship’s Human Resources Leadership team, advising portfolio companies. Before joining Flagship, Michelle was the Global Human Resources Business Leader for Takeda Pharmaceuticals where she was responsible for the creation and execution of HR strategy for therapeutic development in R&D. During her tenure, she led the due diligence and integration of the ARIAD acquisition in 2017. Ms. Smith was the Global Head of Human Resources for Development (R&D) at Sanofi, in addition to holding other positions at Sanofi (and previously Genzyme). Prior to joining the biotech/pharma industry, she held HR positions with Goldman Sachs and Young & Rubicam Advertising in New York City.

Ms. Smith received a B.A. in History from Chestnut Hill College in Philadelphia and currently serves on the Board of Directors for Horse Hugs for Heroes, a therapeutic animal non-profit organization based in Maryland.

Phil focuses on creating and building companies that develop breakthrough therapies for orphan genetic diseases. He is passionate about working with patient groups, and helping to unite those suffering from rare diseases in order to foster a support network and potentially improve patient outcomes.

Phil has authored or co-authored more than 100 articles in scholarly journals and has published seven books including most recently Orphan: The Quest to Save Children with Rare Genetic Disorders. Phil currently serves on the Advisory Board to the Boston University School of Public Health, and has served as a trustee emeritus of Cornell University, an Overseer of Weill Cornell Medical College.

Jim serves as chair of the board of directors of Idera Pharmaceuticals, Orchard Therapeutics, and Pieris Pharmaceuticals, and as a director of Fulcrum Therapeutics. He was previously an entrepreneur-in-residence at Third Rock Ventures and served earlier as senior vice president Strategy and Business Development at Sanofi. Jim held wide-ranging leadership positions at Genzyme, including senior vice president International Development, president of Genzyme Europe, general manager Cardiovascular, and chair and chief executive officer of Genzyme Transgenics. Jim started his career at Bain & Company. He has a B.A. from Georgetown, an M.S. from the University of Pennsylvania, and a J.D. from Yale.